Quality of life improvements in patients with cervical dystonia following treatment with a liquid formulation of abobotulinumtoxinA (Dysport
| Autor: | M. Volteau, Philippe Picaut, W. Poewe, M. Simonetta‐Moreau |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Adult
Male medicine.medical_specialty Spasmodic Torticollis Placebo Injections Intramuscular 03 medical and health sciences 0302 clinical medicine Quality of life Double-Blind Method Rating scale Secondary analysis medicine Humans In patient 030212 general & internal medicine Cervical dystonia Botulinum Toxins Type A Torticollis business.industry Middle Aged medicine.disease Treatment Outcome Neurology Neuromuscular Agents Physical therapy Quality of Life Female Neurology (clinical) business 030217 neurology & neurosurgery |
| Zdroj: | European journal of neurology. 26(6) |
| ISSN: | 1468-1331 |
| Popis: | BACKGROUND AND PURPOSE In patients with cervical dystonia, abobotulinumtoxinA solution for injection (ASI) has been shown to be similarly effective to freeze-dried abobotulinumtoxinA in reducing Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) total scores. In this secondary analysis, quality of life data as evaluated with the Cervical Dystonia Impact Profile (CDIP-58) are presented. METHODS This was a double-blind, randomized, active and placebo-controlled study followed by an open-label extension (NCT01261611). In the double-blind phase, patients were randomized (3:3:1) to one cycle of ASI 500 U (n = 156), abobotulinumtoxinA 500 U (n = 159) or placebo (n = 54). Following the double-blind phase, all patients received open-label ASI for up to four cycles. RESULTS The CDIP-58 total scores were significantly improved at week 4 of the double-blind phase in both the ASI 500 U and abobotulinumtoxinA 500 U groups versus placebo [least squares mean change from baseline of -9.5 (-11.51, -7.45) and -11.2 (-13.2, -9.26) vs. -0.9 (-4.04, 2.14), respectively; both P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text